Okihara K, Babaian R J
Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4095, USA.
Curr Urol Rep. 2001 Jun;2(3):253-8. doi: 10.1007/s11934-001-0088-7.
This article presents the current reports of complexed prostate-specific antigen (PSA) aimed for the enhancement of prostate cancer detection. Further studies are needed to ascertain the variability of complexed PSA. Comparisons of percent free PSA, potential additive value of alpha(1)-antichymotripsin-bound PSA (PSA-ACT) and Bayer complexed PSA (cPSA) remains controversial in men with intermediate elevated total PSA concentration. Volume-referenced complexed PSA (PSA-ACT and cPSA) can enhance prostate cancer detection. Preliminary results show that PSA-alpha(2)-macrobloblin (PSA-a(2)M) and PSA-alpha(1)-protease inhibitor (PSA-API) are promising assays for improving cancer detection.
本文介绍了旨在提高前列腺癌检测率的复合前列腺特异性抗原（PSA）的当前报告。需要进一步研究以确定复合PSA的变异性。在总PSA浓度中度升高的男性中，游离PSA百分比、α1抗糜蛋白酶结合PSA（PSA-ACT）和拜耳复合PSA（cPSA）的潜在附加值比较仍存在争议。体积参考复合PSA（PSA-ACT和cPSA）可提高前列腺癌检测率。初步结果表明，PSA-α2巨球蛋白（PSA-α2M）和PSA-α1蛋白酶抑制剂（PSA-API）是改善癌症检测的有前景的检测方法。
